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Breast cancers in BRCA1 mutation carriers fre-
quently have a distinctive basal-like phenotype. It
has been suggested that this results from an origin
in basal breast epithelial stem cells. Here, we demon-
strate that deletingBrca1 inmousemammary epithe-
lial luminal progenitors produces tumors that pheno-
copy human BRCA1 breast cancers. They also
resemble the majority of sporadic basal-like breast
tumors. However, directingBrca1 deficiency to basal
cells generates tumors that express molecular
markers of basal breast cancers but do not histolog-
ically resemble either human BRCA1 or the majority
of sporadic basal-like breast tumors. These findings
support a derivation of the majority of human
BRCA1-associated and sporadic basal-like tumors
from luminal progenitors rather than from basal
stem cells. They also demonstrate that when target
cells for transformation have the potential for pheno-
typic plasticity, tumor phenotypes may not directly
reflect histogenesis. This has important implications
for cancer prevention strategies.
INTRODUCTION
The epithelial glandular network of the breast comprises two
main cell types, outer basal cells and inner luminal cells. The
majority of the basal cells are differentiated myoepithelial cells
(Sleeman et al., 2007), but this layer also includes the mammary
stem cells (Shackleton et al., 2006; Sleeman et al., 2006; Stingl
et al., 2006; Taddei et al., 2008). The luminal cells include differ-
entiated milk-secreting cells (during lactation) but other func-
tional luminal cell types can be found, such as hormone
receptor-expressing cells (Sleeman et al., 2007). The luminal
layer is also thought to contain a number of different classes of
progenitor, including progenitors for the hormone receptor-ex-
pressing cells (Booth and Smith, 2006) and secretory cells
(Oakes et al., 2008). These different epithelial lineages can be
separated by flow cytometric analysis of expression levels of
CD24, Sca-1, and CD49f antigens (Kendrick et al., 2008;CellSleeman et al., 2007; Stingl et al., 2006). The myoepithelial cells
of the basal layer are defined as CD24+/low Sca-1 CD49flow,
whereas the basal stem cells are enriched in the CD24+/low
Sca-1 CD49fhigh cell fraction. Luminal estrogen receptor-posi-
tive (ER+) cells have the phenotype CD24+/high Sca-1+ whereas
luminal CD24+/high Sca-1 cells are largely ER progenitors.
Tissue stem cells are good candidates for the cells of origin of
tumors, because their long in vivo lifespanmeans they can accu-
mulate the mutations required for tumor formation (Smalley and
Ashworth, 2003). It is also possible that progenitors downstream
of stem cells could accumulate enough genetic lesions to
generate a tumor (Dontu et al., 2003), depending on their rate
of turnover. In breast cancer, it is proposed that different tumor
subtypes (Sorlie et al., 2003) may originate from different classes
of stem/progenitor cells, with ER ‘‘basal-like’’ breast cancers
originating from ER basal stem cells and ER+ luminal breast
cancers from progenitors committed to luminal ER+ differentia-
tion (Dontu et al., 2003; Melchor and Benı´tez, 2008). Strikingly,
the majority of breast tumors arising in carriers of germline muta-
tions in BRCA1 have the basal-like phenotype (Lakhani et al.,
2005; Palacios et al., 2005). It has therefore been proposed
that loss of BRCA1 function in basal stem cells results in tumor
formation associated with a block in luminal differentiation
(Foulkes, 2004; Liu et al., 2008; Vassilopoulos et al., 2008). In
contrast, recent work showed an increase in luminal progenitor
numbers in breast tissue ofBRCA1mutation carriers and a corre-
lation between the gene expression profile of normal human
luminal progenitors and basal-like breast cancers (Lim et al.,
2009). However, despite the association of aberrant luminal
progenitors with BRCA1 mutations, an origin of BRCA1 breast
cancers in luminal progenitors was not directly demonstrated.
To achieve this, a direct comparison of the effects of creating
identical tumor predisposing events in stem versus progenitor
cells is required. Here we describe such a comparison. We have
directed Brca1 loss of function either predominantly to basal or
luminal mammary epithelial cells, thereby biasing tumor origin
to basal stem cells, or to progenitors of the luminal layer.
In both systems, the molecular features of the tumors that arise
are similar to those of human basal-like tumors. However, only
tumors originating in luminal progenitors have the same histolog-
ical appearance as human BRCA1 tumors and indeed resemble
the majority of human sporadic (nonfamilial) basal-like breast
cancers. In contrast, Brca1 loss in basal stem cells preferentially
generated malignant adenomyoepitheliomas, which are rareStem Cell 7, 403–417, September 3, 2010 ª2010 Elsevier Inc. 403
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Luminal Origin of Basal-like Breast Cancerstumors in humans, with features consistent with a stem cell
origin. Importantly, these results reconcile conflicting data from
other investigators, showing that deletion of Brca1 in stem cells
causes accumulation of cells with a very strong basal phenotype
(Liu et al., 2008), but only deletion of Brca1 in luminal progenitors
produces tumors resembling human BRCA1 mutation-associ-
ated breast cancers (Lim et al., 2009). Our findings suggest
that malignant adenomyoepitheliomas are true stem cell tumors
but, given the comparative rarity of this tumor type in humans,
also highlight luminal progenitors as the key to understanding
much of the etiology of breast cancer. The finding that normal
mammary gland stem cells may not be common targets for
transformation in the breast has important implications for
strategies to treat and prevent breast cancer.
RESULTS
The Blg Promoter Is Active in Progenitor Cells
with a Luminal Sca-1– ER– Phenotype
We have previously described a Cre-loxP-based mouse model
of breast cancer in which Cre expression was under the control
of the Blg promoter and animals were put through two rounds of
pregnancy to drive maximum levels of conditional allele recom-
bination (McCarthy et al., 2007). Mammary tumors developed
in these mice but the cells of origin of these tumors were
unknown, although the Blg promoter is thought to be mainly
active in luminal cells (Naylor et al., 2005). We therefore set out
to define in detail the cell lineages in which Blg-Cre-mediated
recombination occurs in the mammary epithelium by using
Rosa26 Reporter (R26R) mice, in which Cre activity permanently
switches on b-galactosidase expression.
CD24+/low Sca-1 basal, CD24+/high Sca-1 luminal ER, and
CD24+/high Sca-1+ luminal ER+ mammary epithelial cells were
isolated from four groups of mice: virgin Blg-Cre R26R mice at
12 weeks, 21 weeks, and 42 weeks of age and also mice that
had undergone two full-term pregnancies, each followed by
3 weeks of lactation and normal weaning. These animals (here-
after termed ‘‘parous’’ mice) had weaned their last litter by
18weeks of age and cellswere harvested from themat 21weeks,
to allow for postweaning involution and remodeling. In each
group, separated cells were cultured as single-cell clones for
10 days in vitro and then stained for b-galactosidase (R26R
reporter) activity (Figure 1; Figure S1 available online). The
proportion of cells in each population with colony-forming poten-
tial (progenitors) that were b-galactosidase+ (‘‘recombined’’
progenitors) was calculated (see Experimental Procedures).
In the 12-week-old virgin mice, the majority of colonies derived
from luminal ER cells were b-galactosidase positive, whereas
very few luminal ER+-derived colonies were positive and no
detectable b-galactosidase activity was found in basal-derived
colonies. By 21 weeks, almost all virgin luminal ER cell-derived
colonies were b-galactosidase positive. However, approxi-
mately half of colonies derived from luminal ER+ cells were
also positive and b-galactosidase activity could be detected in
occasional basal cell-derived colonies. By 42 weeks, many posi-
tive colonies were seen in the virgin basal cell cultures, although
this varied considerably from preparation to preparation. Inter-
estingly, the distribution of b-galactosidase-positive colonies
derived from the 21-week parous mice was almost identical to404 Cell Stem Cell 7, 403–417, September 3, 2010 ª2010 Elsevier Inthat of the 42-week virgin mice. These results demonstrated
that Cre-dependent recombination saturated the luminal ER
population relatively quickly in virgin animals but also suggested
that Cre-expressing progenitors from this population were
contributing to estrous cycle-dependent remodeling of the
tissue and regeneration of the basal and luminal ER+ cell layers.
Pregnancy accelerated the accumulation of recombined cells in
the basal population. In all groups, however, the Blg-Cre trans-
gene was clearly most strongly active in the luminal ER popula-
tion. Furthermore, it was clear that at all developmental stages,
the luminal ER population contained a far higher proportion of
recombined progenitors than any other population.
Blg-Cre Brca1f/f p53+/– Mice Develop Mammary Tumors
that Phenocopy Human BRCA1 Loss-of-Function Breast
Cancers
Although Blg-Cre transgene activity resulted in conditional allele
recombination in almost all progenitors in the luminal ER popu-
lation, in parous and older virgin animals recombinant alleles
could be detected in cells from the basal layer, which contains
the mammary stem cells. Therefore, it was still possible that
basal stem cells could be the primary targets for Blg-Cre-driven
tumor formation. To address this, we established cohorts of
virgin and parous Blg-Cre Brca1f/f p53+/ mice and monitored
them for tumor formation. The results were compared with
samples from a cohort of virgin K14-Cre Brca1f/f p53+/ mice,
in which Cre expression was driven by the Keratin 14 promoter.
Keratin 14 (K14) is expressed in basal cells in the mouse
mammary epithelium (Sleeman et al., 2006), although in humans,
K14 can also be expressed in luminal cells (Gusterson et al.,
2005). Importantly, K14 is expressed by human (Pece et al.,
2010) and mouse (Jonkers et al., 2001; Sleeman et al., 2007)
mammary stem cell populations. We confirmed this by quantita-
tive real-time PCR (qPCR) analysis of Krt14 gene expression in
luminal ER, luminal ER+, myoepithelial (CD24+/low Sca-1
CD49flow), and mammary stem cell-enriched (CD24+/low Sca-
1 CD49fhigh) populations (Sleeman et al., 2007). Interestingly,
this demonstrated that Krt14 gene expression in mammary
stem cell-enriched cells was significantly higher (1.6-fold) even
than that in myoepithelial cells (Figure S2A).
If recombined cells in the basal population made a significant
contribution to tumor formation in the Blg-Cre animals, then
parity would be expected to accelerate the rate of tumor onset
as it accelerates the accumulation of these cells. However, there
was no significant difference in age or rate of mammary tumor
onset between virgin and parous Blg-Cre Brca1f/f p53+/ mice,
with a median latency of 336 and 319 days, respectively. In con-
trast, onset of K14-Cre Brca1f/f p53+/ tumors was significantly
faster than both Blg-Cre cohorts (log-rank test, p < 0.001), with
amedian latency of 249 days (Figure 2A). All tumors except three
(from the virgin Blg-Cre cohort) showed a significant (p < 0.05)
reduction in p53 expression compared to spleens from wild-
type animals of a similar mixed genetic background (Figure S2B).
For Brca1, exon 22 expression was decreased in the majority of
tumors to a greater extent than exon 19 expression, consistent
with deletion of floxed exon 22 from the conditional Brca1 allele.
In one tumor (K14-Cre 3265), Brca1 expression levels were
increased compared to spleen. The reasons for this are unclear
(Figures S2C and S2D).c.
Figure 1. The Blg-Cre Transgene Is Active Primarily in Luminal ER– Cells
(A–D) Flow cytometry of cells from virgin Blg-Cre R26R mice at 12 weeks (A), 21 weeks (B), and 42 weeks (C) and from 21-week parous mice (D) indicating the
CD24+/low Sca-1 basal (red), CD24+/high Sca-1 luminal ER (green), and CD24+/high Sca-1+ luminal ER+ (blue) regions used to isolate cells for in vitro colony-
forming assays.
(E) Results of the colony-forming assays. Each data set is from three independent isolations of each population. The total number of colonies counted, the total
number of 96-well plates analyzed, the mean percentage (±standard deviation; SD) of b-galactosidase+ colonies, and the proportion of recombined progenitors
within each population at each developmental stage are indicated.
See also Figure S1.
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Luminal Origin of Basal-like Breast CancersThe phenotype of both the virgin and parous Blg-Cre Brca1f/f
p53+/ tumors was similar (Figures 2B–2I; the properties of all
the tumors are described in Table S1). They were classifiedCellmainly as invasive ductal carcinomas of no special type (IDC-
NST), typically with central necrosis (Figure 2B; asterisk), and
pushing (Figures 2B and 2C; arrows) or mixed borders.Stem Cell 7, 403–417, September 3, 2010 ª2010 Elsevier Inc. 405
Figure 2. Histological Features of Tumors from Virgin Blg-Cre Brca1f/f p53+/– Mice but Not K14-Cre Brca1f/f p53+/–Mice Resemble Those of
the Majority of Human BRCA1 Tumors
(A) Kaplan-Meier tumor latency curve of K14-Cre Brca1f/f p53+/, virgin Blg-Cre Brca1f/f p53+/, and parous Blg-Cre Brca1f/f p53+/ animals. Only data from
animals developing mammary tumors is shown. The latency of K14-Cre tumors was significantly shorter (p < 0.001; Log rank test) than that of either virgin or
parous Blg-Cre Brca1f/f p53+/ tumors.
(B–I) Histological features of Blg-Cre Brca1f/f p53+/ tumors.
(B) IDC-NST showing central necrosis (asterisk) and pushing margins (arrow). Scale bar represents 0.4 mm.
(C) Tumor with pushing margins (arrows). Scale bar represents 270 mm.
(D) Tumor showing chondroid metaplasia (asterisk). Scale bar represents 110 mm.
(E) High-power image showing aberrant mitotic figures (arrows) and conspicuous nuclear pleomorphism. Scale bar represents 27 mm.
(F) K14 expression in epithelioid and spindloid neoplastic cells.
(G) K18 expression in epithelioid neoplastic cells.
Scale bars in (F) and (G) represent 110 mm.
(H) p63 expression in neoplastic cells. Scale bar represents 55 mm.
(I) ER staining in an ER tumor. The arrow indicates the region enlarged in the inset. Note that this region includes a normal duct entrapped at the edge of the tumor
containing ER+ luminal cells (arrowheads). Scale bar represents 110 mm.
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Luminal Origin of Basal-like Breast CancersMetaplastic elements in the form of spindle and/or squamous
cell metaplasia were found in 12 out of 14 cases from virgin
animals and 9 out of 10 from parous animals. In one virgin tumor,
chondroid metaplasia was also observed (Figure 2D; asterisk).
All Blg-Cre tumors were classified as histological grade 3, dis-
playing a high degree of nuclear pleomorphism, little or no tubule
formation, and a high mitotic index, often with aberrant mitotic
figures (Figure 2E, arrows). All were positive for basal K14
(Figure 2F). Ten cases from virgin animals and 10 from parous
animals were positive for luminal Keratin 18 (K18) (Figure 2G),
with staining for both K14 and K18 seen in both epithelioid and
metaplastic spindle cells. Eight cases from virgin animals and
five from parous animals were positive for the basal marker
p63 (Figure 2H). Only three tumors from virgin animals and two
from parous animals were ER+ (Figure 2I). In summary, these
tumors displayed histological and immunohistochemical
features that closely recapitulated the cardinal features of human
BRCA1 breast tumors. In particular, most displayed features
characteristic of the majority of human basal-like breast cancers
(Rakha et al., 2008).K14-Cre Brca1f/f p53+/–Mice DevelopMammary Tumors
that Do Not Resemble Human BRCA1 Loss-of-Function
Breast Cancers
Compared to the Blg-Cre cohorts, the balance of tumor pheno-
types in the K14-Cre Brca1f/f p53+/ tumors was reversed
(Figures 2J–2O and 3A). Only one tumor was classified as an
IDC-NST but seven of the eight available for analysis were
classed as adenosquamous (metaplastic) carcinoma or malig-
nant adenomyoepithelioma (Figure 2J). In the latter, distinct
malignant luminal-like and basal-like populations could be
observed in an arrangement reminiscent of that of the normal
mammary ductal morphology (Figure 2K), features consistent
with a stem cell origin. All tumors were strongly K14 and p63
positive (Figures 2L and 2N). Seven tumors were also K18 posi-
tive (Figure 2M) but five were ER (Figure 2O). The percentage of
K14-positive cells within the tumors in the three cohorts fell into
a similar range (although it tended to be slightly higher in the
K14-Cre tumors) (Figure 3B). However, the percentage of
K18-positive cells was higher in the parous Blg-Cre tumors
compared to the K14-Cre tumors, whereas the virgin Blg-Cre
tumors had a bimodal distribution of K18 staining (Figure 3B).
In contrast, the percentage of p63-positive cells was higher in
the K14-Cre tumors compared to the parous Blg-Cre tumors,
whereas the virgin Blg-Cre tumors again had a bimodal distribu-
tion (Figure 3B). This suggested that the K14-Cre tumors had
a more overt basal-like differentiation, the parous Blg-Cre(J–O) Histological features of K14-Cre Brca1f/f p53+/ tumors.
(J) Low-magnification micrograph of malignant adenomyoepithelioma. Scale bar
(K) High-power image showing gland-like structures lined by two neoplastic cell p
basal cells (arrow), suggesting that the pseudobasal cells are contributing to the
(L) K14 expression in neoplastic cells (arrow indicates area enlarged in inset). No
(M) K18 was strongly expressed in luminally located cells (inset; arrow indicates
Scale bars in (L) and (M) represent 110 mm.
(N) p63 expression in pseudobasal neoplastic cells. Scale bar represents 55 mm
(O) ER expression in an ER K14-Cre tumor. The arrow indicates an area of hyperp
staining (enlarged in the inset). Scale bar represents 110 mm.
See also Figure S2 and Table S1.
Celltumors were more luminal-like, and the virgin Blg-Cre tumors
were, as a group, intermediate between the two.
Tumors from all three cohorts had a high mitotic index, which
contributed to them being classified as grade 3. However, when
mitotic counts were considered, parous Blg-Cre tumors were
found to be slightly, but significantly (p < 0.05, unpaired two-
tailed t test), more proliferative than virgin Blg-Cre tumors, with
on average 145 mitotic figures (95% confidence limits, 102 to
188) and 95 mitotic figures (95% confidence limits, 72 to 118)
per 10 high-power fields, respectively. Remarkably, the K14-
Cre tumors were even more proliferative, with 296mitotic figures
(95% confidence limits, 218 to 373) in 10 fields (p < 0.001,
unpaired two-tailed t test against parous Blg-Cre tumor data)
(Figure 3B). The features of these K14-Cre tumors were, there-
fore, consistent with an origin in stem cells with a high prolifera-
tive potential.
The profound differences in the histopathological features
between tumor cohorts that vary only in the promoter used to
drive gene expression are highly likely to be the result of different
cells of origin. The patterns of expression of the K14 and Blg
promoters within the mammary gland (Figure 1; Figure S2A;
Jonkers et al., 2001) and the comparative phenotypes of the
tumors support a model in which the K14-Cre promoter biases
tumor formation to basal stem cells whereas the Blg-Cre
promoter biases tumor formation to progenitors in the luminal
layer.Blg-Cre Brca1f/f p53+/– Tumors Have a Basal Flow
Cytometric Profile
To further investigate the appearance of cells with a basal-like
phenotype in luminal progenitor-origin Brca1 tumors, we used
flow cytometry to compare normal epithelial cells isolated from
young (12-week) and aged (42-week) virgin mice with tumor cells
stained for CD24, Sca-1, and CD49f expression. Changes in the
proportion of CD24 nonepithelial, CD24+/low basal, and
CD24+/high luminal cells (Figure 3C) as well as in numbers of cells
with the basal stem cell-enriched phenotype (CD24+/low Sca-1
CD49fhigh) were quantified (Figure 3D). Both the tumors and aged
virgin normal cells showed an increase in the proportion of
CD24+/low cells and a decrease in CD24+/high cells compared to
young normal mice. However, the tumors also showed signifi-
cant enrichment for cells with a stem cell-like phenotype
(CD24+/low Sca-1CD49fhigh) aswell as the appearance of a pop-
ulation with the phenotype CD24+/high Sca-1 CD49fhigh (Figures
3C and 3D; Figure S3A).
Enrichment within the tumors for cells with a stem cell-like flow
cytometry phenotype led us to speculate that they may containrepresents 0.4 mm.
opulations. Note the mitotic figure with plane of division along axis of pseudo-
luminally located cells. Scale bar represents 27 mm.
te that the luminally located cells often lack K14 expression (inset).
enlarged area).
.
lasia entrapped within the tumor that acts as an internal positive control for the
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Figure 3. Blg-Cre Tumors Have Enhanced Luminal Histological Features Compared to K14-Cre Tumors but Are Enriched for CD49f
Expression
(A) Prevalence of histopathological phenotypes of Blg-Cre and K14-Cre tumors. Abbreviations: IDC-NST, invasive ductal carcinoma, no special type; adenomyo,
malignant adenomyoepithelioma; metaplastic, metaplastic carcinoma (includes metaplastic spindle cell carcinoma and adenosquamous carcinoma).
(B) Distribution of K14-, K18-, and p63-positive cells within the tumor cohorts and comparative mitotic indices (mitotic figures counted in 10 high-power fields in
each tumor of each cohort; bars indicate median values). Each data point represents an individual tumor.
(C and D) CD24 and Sca-1 (C) or CD24 and CD49f (a6 integrin) (D) flow cytometry staining of normal mouse mammary epithelium (left plots; used as gating refer-
ence) and cells isolated from virgin Blg-Cre tumors (right plots). Below the plots comparisons are shown of the proportions (±SD) of CD24 (unshaded bars),
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Luminal Origin of Basal-like Breast Cancersa distinct population of ‘‘tumor-initiating cells’’ or ‘‘cancer stem
cells.’’ Therefore, we carried out limiting dilution transplant
assays on cells from virgin Blg-Cre Brca1f/f p53+/ tumors sepa-
rated on the basis of levels of CD24 expression. These experi-
ments proved technically challenging, because very few viable
cells could be recovered from tumors after dissociation and
flow sorting (Figure S3A). Nevertheless, we were able to carry
out limiting dilution transplant series of dissociated cells from
two tumors (three further samples were transplanted at limiting
dilutions but failed to form any secondary tumors and so are
excluded from the analysis). The results showed that tumor cells
with an undifferentiated CD24 Sca-1 phenotype were most
highly enriched for tumor-initiating cells, with 1 in 1949 cells
having tumor-initiating potential compared to 1 in 7061 cells in
theCD24+/low Sca-1 population (Table S2). It is the latter pheno-
type which is associated with the stem cell population in normal
mammary epithelium, so this demonstrated that in tumors the
stem cell surface marker phenotype does not necessarily corre-
late with functional potential.
During this analysis, we collected extensive data on the flow
cytometric profiles of primary, secondary, and tertiary trans-
planted tumors. Remarkably, they were very different, with at
least four different types of profile observed (Figure 3E). There
was no correlation between the type of profile and the tumor
subpopulation from which the new generation of tumor had
been grown. Rather, the profiles suggested that clonal selection
was occurring, possibly within a pool of cancer stem cell-like
cells (Marusyk and Polyak, 2010).
We examined whether the balance of mammary epithelial
populations was altered in Blg-Cre mice carrying floxed Brca1
alleles at an age where recombination has occurred only in the
luminal ER progenitor population but prior to tumor formation
(10–12 weeks). There were no significant differences (two-tailed
t test on Log10 transformed data) between the proportions of
basal and luminal ER+ cells in mice with various combinations
of Brca1 and p53 alleles compared to each other or control
Blg-Cre R26R mice. However, Blg-Cre Brca1f/f p53+/ animals
had a significantly reduced (two-tailed t test on Log10
transformed data, p < 0.05) proportion of luminal ER cells
compared to Blg-Cre Brca1f/+ p53+/ animals (Figure S3C).
The significance of this is unclear, however, because in neither
genotype was the proportion of luminal ER cells significantly
different to wild-type. Nevertheless, the results do support the
luminal ER progenitor population as the primary target of
Blg-Cre activity.
Gene Expression Profiles of Brca1f/f p53+/– Tumors
Resemble Those of Luminal Sca-1– ER– Cells
To determine whether the basal-like differentiation observed by
histopathology and flow cytometry in luminal origin Blg-CreCD24+/low (light gray bars), and CD24+/high cells (dark gray bars) (C) or of CD24+/low
three independent preparations of 12-week and 42-week normal virgin mice and
(E) Flow cytometric analysis of transplanted tumors. Top row, CD24 and Sca-1 sta
from transplantation of tumor #14. Bottom row, CD24 and Sca-1 profiles of four te
isolated for transplant analysis are indicated. The population of origin, number o
tertiary tumor.
See also Figure S3 and Table S2.
CellBrca1f/f p53+/ tumors was reflected at the molecular level, the
gene expression profiles of 12 virgin and 6 parous Blg-Cre
Brca1f/f p53+/ tumors and 3 K14-Cre Brca1f/f p53+/ tumors
were analyzed. A set of 2184 Affymetrix probes known to
robustly distinguish between normal basal, luminal ER, and
luminal ER+ cells (Kendrick et al., 2008) was used for unsuper-
vised hierarchical clustering of the tumors (Figure 4A). Further,
both the 2184 subset and the entire probe data set were used
for a prediction analysis of microarrays (PAM) approach in which
the expression pattern of the normal populations was used as
a training set to build a classifier. This was applied to the
expression data from the tumors to identify which normal cell
population the tumors most closely resembled (Figure 4A and
Table S3; similar results were obtained for both the 2184 subset
and the entire data set). These data showed that 16 out of
21 tumors, including 2 of the 3 K14-Cre tumors, most closely
resembled luminal ER cells in their gene expression profiles.
Four out of five tumors classified as basal-like by PAM clustered
with each other and with the normal basal cells. However, the
virgin Blg-Cre, parous Blg-Cre, and K14-Cre tumors did not
segregate into separate groups.
The gene expression microarray data suggested substantial
similarity in the molecular pathological phenotype between the
three tumor cohorts. To analyze this further, we used
qPCR-based gene expression analysis on a subset of genes
whose expression was associated with the normal epithelial
subtypes (Kendrick et al., 2008). We were also able to use
qPCR to address gene expression profiles in a larger number
of K14-Cre tumors than were available for analysis by microar-
ray. The results confirmed the microarray data, showing that all
cohorts expressed genes associated with luminal ER and basal
cell populations but not with luminal ER+ cells. Unsupervised
hierarchical clustering of the qPCR data showed that, when
the additional K14-Cre tumors were included, they tended to
cluster with the normal basal cell populations. Three Blg-Cre
tumors classified by PAM as most similar to normal basal cells
(9, 36.1, and 7165) also clustered with this group (Figure 4B).
Although this clustering did separate tumors more obviously
according to their cells of origin, it was clear that overall the
tumor cohorts had similar gene expression patterns (Figures
4B and 5). There were some exceptions consistent with the
histopathology of the tumors. For instance, Trp63 expression
was higher in the K14-Cre cohort than the parous Blg-Cre
cohort, but in the virginBlg-Cre cohort, Trp63 expression ranged
from very low to high expression levels. The basalmarker Id4 had
a similar pattern of expression (Figure 5). In conclusion, despite
the different histological features of the K14-Cre and Blg-Cre
tumors, they had a similar (but not identical) gene expression
profile that most closely resembled that of the normal luminal
ER cells.CD49fhigh (unshaded bars) and CD24+/high CD49fhigh cells (dark gray bars) (D) in
nine virgin Blg-Cre tumors.
ining profile of a primary tumor, #14, and four secondary tumors that originated
rtiary tumors from transplantation of tumor #37. The populations P1, P2, and P3
f cells transplanted, and tumor latency are indicated on each secondary and
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Figure 4. Most Brca1f/f p53+/– Tumors Have
a Luminal ER– Gene Expression Profile
(A) Unsupervised hierarchical clustering and PAM
analysis of tumor gene expression data with data
from normal mouse mammary epithelial subpopu-
lations. Clustering is based on the expression of
the 2184 cell-specific probes previously identified
(Kendrick et al., 2008). PAM results are indicated
by color coding below the tumors samples, with
green indicating closest similarity to normal
luminal ER cells and red to normal basal cells.
No tumors were similar to luminal ER+ cells (blue).
(B) Heat map of gene expression patterns from
qPCR analysis of tumor samples based on relative
expression levels of 14 genes compared to
a comparator population (normal CD24+/high
Sca-1 luminal ER cells). Genes analyzed were
a selection known to be associated with normal
basal (Frd7, Id4, Krt14, Krt17, Runx2, Trp63, and
Twist), luminal ER (Elf5, Foxc1, Kit, Fabp7),
luminal ER+ (Esr1, Foxa1) mammary cells, and
cells from both luminal populations (Krt18)
(Kendrick et al., 2008). Tumor samples and genes
were clustered in an unsupervised manner. The
data from the normal populations are from three
separate isolates of the normal cell populations
from mice with a mixed genetic background,
each measured in triplicate. Data from individual
tumor samples were also measured in triplicate.
See also Table S3.
Cell Stem Cell
Luminal Origin of Basal-like Breast CancersMouse Brca1f/f p53+/– Tumors Are Classified as
Basal-like via Human Class Predictor Gene Sets
Only tumors from the luminal Blg-Cre Brca1f/f p53+/ cohorts
resembled human BRCA1 tumors with respect to histopatho-
logical phenotype (Figure 2). However, the majority of human
BRCA1 tumors are classified by gene expression analysis as
most similar to ‘‘basal-like’’ nonfamilial (sporadic) breast
cancers (Sorlie et al., 2003), whereas the mouse tumors
tended to have gene expression patterns that most closely
resembled normal mouse luminal ER cells (Figure 4A). We
therefore asked which human breast tumor subtype the mouse
tumors most closely resembled. Two single sample predictor
gene sets (SSPs) that have been used previously to predict
human breast cancer molecular subtypes (Hu et al., 2006;
Parker et al., 2009) were used to predict, according to the
human classification, the phenotype of the mouse tumors.410 Cell Stem Cell 7, 403–417, September 3, 2010 ª2010 Elsevier Inc.Although doubt has recently been cast
on the ability of SSPs to reliably identify
luminal, HER2, and normal breast-like
breast cancer subtypes, it is clear that
they do robustly distinguish basal-like
from non-basal-like breast cancers
(Weigelt et al., 2010). Notably, all tumors
were classified as basal-like, according
to the Hu306 centroids (Hu et al.,
2006). Furthermore, 18 out of 21 tumors
were classified as basal-like according
to the more recently published PAM50
gene set (Figure 6; Table S3; Parker
et al., 2009).We next considered whether sporadic human basal-like
breast cancers expressed genes associated with luminal ER
cells. First, we used self-organizing mapping analysis of the
patterns of expression of the 2184 probe subset in the virgin
Blg-Cre tumors to identify groups of genes expressed at high
levels across all tumors (Table S4). Then we identified genes
expressed at high levels in the tumors whose expression was
associated with the normal luminal ER cell population. We
examined the distribution of these genes in a panel of 53 grade
3 human breast cancers (Natrajan et al., 2010) (including both
luminal and basal subtypes defined according to Nielsen’s
criteria) (Nielsen et al., 2004) and in the NKI295 tumor gene
expression data set (Table 1; Table S5; van de Vijver et al.,
2002). In the former set, 69 of themouse genes could be robustly
mapped to human orthologs. 21 had a significant subtype
association and of these, 18 (86%) were associated with the
Figure 5. qPCR Analysis of Gene Expression in Tumor Cohorts
Mean gene expression levels (±95% confidence limits) for a subset of the genes shown in Figure 4B (Id4, Trp63, Elf5, Fabp7, Foxc1, and Esr1) in normal luminal
ER, luminal ER+, myoepithelial (CD24+/low Sca-1 CD49flow), and basal stem cell-enriched (CD24+/low Sca-1 CD49fhigh) cells and in the individual tumors, rela-
tive to the comparator population (which were the luminal ER cells). The data from the normal populations are from three separate isolates of the normal cell
populations from mice with a mixed genetic background similar to the Blg-Cre Brca1f/f p53+/ mice, each measured in triplicate. Data from individual tumor
samples were also measured in triplicate. The normal populations and the three tumor cohorts are grouped together. Within each cohort data are ordered
left to right from lowest to highest gene expression levels. If a tumor sample is not present on the graph, then RNAwas not available for analysis. Asterisk indicates
that expression of a particular gene was undetectable in that sample.
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Figure 6. Brca1f/f p53+/– Tumors Resemble Human
Sporadic Basal-like Breast Cancers
Heat map of expression of genes (red, high expression; green,
low expression) from the PAM50 breast subtype classifier
gene sets in mouse tumors. Samples are clustered on the
basis of expression of the PAM50 genes and the single sample
predictor correlations with human tumor subtypes for both the
PAM50 and Hu306 gene sets are shown below the clustering
tree (green, luminal A; blue, luminal B; gray, HER2; black,
normal breast-like; red, basal-like; open, unclassifiable). See
also Table S3.
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In the NKI data set, 61 orthologs of the mouse genes could be
identified. 39 of these had a significant subtype association
and 26 (67%) were associated with the basal-like subtype
(p < 0.01, two-tailed Fisher exact test). These analyses demon-
strate that genes typically expressed by ER cells of the luminal
mammary epithelium are also expressed by sporadic human
basal-like breast cancers, consistent with the SSP classification
of the mouse tumors.
Finally, gene set enrichment analysis (GSEA) (Subramanian
et al., 2005) was used on the expression profiles to identify func-
tionally or phenotypically relevant sets of genes enriched in the
tumors compared to the normal cell populations. Notably, this
analysis demonstrated that the tumors were enriched for genes
expressed at high levels in human ER BRCA1 loss-of-function
tumors (p < 0.01; FDR q value 0.393) (Table S6).412 Cell Stem Cell 7, 403–417, September 3, 2010 ª2010 Elsevier Inc.DISCUSSION
We have directly compared tumor formation in
mammary epithelial basal stem and luminal
progenitor cells to address not only the roles of
stem and progenitor cells in tumorigenesis but
also the relationship between the cell of tumor
origin and tumor phenotype. We have shown that
targeting deletion of Brca1 to the basal cell layer,
and thus biasing tumor formation to basal stem
cells, preferentially resulted in the development of
aggressive malignant adenomyoepitheliomas. In
humans these are rare tumors consisting of two
distinct neoplastic populations with basal-like and
luminal-like features, consistent with a stem cell
origin. Importantly, they are distinct from benign
proliferations of myoepithelial cells. In contrast,
deleting Brca1 in luminal progenitors preferentially
generated IDC-NSTs that not only phenocopied
human BRCA1 basal-like breast cancers but also
had a strong resemblance to the majority of
basal-like tumors not associated with a family
history of breast cancer (‘‘sporadic’’ basal-like
tumors). These results suggest that malignant ad-
enomyoepitheliomas are true stem cell tumors of
the breast but, given the rarity of this tumor type
and its lack of association with BRCA1 disease,
that normal mammary gland stem cells are not
common targets for transformation in the breast
and certainly make little contribution to the originsofBRCA1-associated breast cancer. Rather, luminal progenitors
are probably the cell type most commonly associated with the
initiation of breast cancer.
Although tumors originating in different cell types had distinct
histological appearances, their gene expression patterns had
similarities. Tumors from all cohorts tended to express genes
associated with both normal basal and luminal ER cells and
to have low levels of expression of luminal ER+ genes (Figures
4B and 5). All tumors were classified as ‘‘basal-like’’ by the
Hu306 and PAM50 single sample predictor (SSP) analysis (with
the exception of tumors 18, 24, and 7148, which were classed
as HER2-like by the PAM50 SSP). However, the K14-Cre cohort
had higher overall levels of expression of basal-associated
genes, consistent with their origin, and clustered with the normal
basal populations (Figure 4B). These results suggest that the cell
of origin of a tumor is one of the key determinants of the tumor
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profile. In contrast, BRCA1 loss primarily determines the molec-
ular landscape of the tumor but also has some influence on its
histological appearance.
In contrast to our K14-Cremodel, Liu and colleagues reported
a K14-Cre Brca1f/f p53f/f mouse model in which the tumors
obtained were mainly IDC-NSTs, with only one adenomyoepi-
thelioma (Liu et al., 2007). Remarkably, the tumor spectrum
they reported is similar to that seen in our Blg-Cre model. There
are a number of differences between the two K14-Cre models,
which may explain these discrepancies. These include different
background strains, different K14-Cre transgenes, and different
floxed Brca1 alleles. Liu and colleagues also used a floxed p53
allele, rather than the p53 heterozygote background. Any of
these factors could alter the relative likelihood of targeting
Brca1 loss to stem versus progenitor cells, or their relative
susceptibility to transformation, resulting in enhanced tumor
formation in luminal progenitor cells in the K14 model of Liu
and colleagues and hence a tumor spectrum similar to our
Blg-Cre model. The importance of the interaction between p53
and Brca1 in transforming basal stem cells is suggested
by data from Smart and colleagues, who reported no mammary
phenotype in a K14-Cre conditional Brca1mouse line on a wild-
type p53 background, unlike inWAP-Cre andMMTV-Cre-driven
Brca1 knockout models (Smart et al., 2008).
It is formally possible that use of the p53 heterozygote back-
ground in the tumor models may alter the predicted cell type
specificity of the promoters used to drive Cre expression, given
the role of p53 in controlling polarity in mammary stem cell divi-
sion (Cicalese et al., 2009). However, p53 heterozygosity has not
been investigated in this context. In our model, p53 gene expres-
sion levels in Blg-Cre Brca1f/f p53+/ spleens and three tumors
(14, 15, and 25) were not significantly different to those of wild-
type animals. Thus, although the mice were p53 heterozygous,
there was little evidence of p53 haploinsufficiency, at least at
the ages at which tumors were developing (Figure S2).
p53-dependent changes in stem cell dynamics prior to deletion
of the Brca1 floxed allele are therefore unlikely to alter the target-
ing of Cre activity. We also cannot definitively exclude the possi-
bility that modifier genes linked to the Blg-Cre or K14-Cre loci
influenced the difference in tumor phenotypes. However,
because the differences were a change in the balance of the
tumor phenotypes rather than absolute changes in tumor type,
this hypothesis is unlikely.
Blg-Cre activity resulted in a small number of recombined
progenitors (i.e., cells with proliferative potential) in the luminal
ER+ population, suggesting that ER+ progenitors could be the
origin of some tumors. However, the Blg-Cre transgene primarily
drove recombination in luminal ER progenitors (Figure 1), sup-
porting these cells as the main target for Blg-Cre Brca1f/f p53+/
tumor formation. When purified and transplanted into cleared fat
pads, the luminal ER population produced multilineage epithe-
lial outgrowths containing myoepithelial, luminal ER, and
luminal ER+ cells, although at lower frequency and with less
extensive outgrowths than are generated after transplantation
of basal stem cells (Sleeman et al., 2007). This demonstrates
that the luminal ER population includes a proportion of cells
with context-dependent multilineage differentiation capacity.
Transformation of mouse luminal ER cells and the generationCellof tumors containing cells with both luminal ER and basal
phenotypes could therefore be a result of destabilization of the
progenitor phenotype and aberrant activation of normally tightly
controlled differentiation programs. It has been reported that
human luminal progenitors are lineage restricted and do not nor-
mally show basal differentiation potential (Lim et al., 2009).
However, it is well established that some luminal epithelial cells
within the human TDLU express ‘‘basal’’ keratins (Gusterson,
2009; Gusterson et al., 2005), suggesting that expression of
some basal markers is an aspect of normal differentiation of
a subset of human luminal cells. Furthermore, BRCA1 loss is
itself likely to result in upregulation of expression of basal-asso-
ciated genes (Gorski et al., 2010; Hosey et al., 2007). This could
contribute to the shift toward basal-like differentiation patterns,
although clearly many cells in ‘‘basal-like’’ BRCA1 tumors retain
a fundamentally luminal identity.
Besides the inherent differentiation potential of the cells of
origin of the Blg-Cre tumors and the effects of BRCA1 loss on
transcription, phenotypic plasticity in the Blg-Cre cohort was
added to bymetaplasia and, potentially, epithelial-mesenchymal
transition (EMT). Metaplasia is widely seen in preneoplastic
conditions such a Barrett’s esophagus (Barbera and Fitzgerald,
2009) and is considered to facilitate tumor development
(Mesquita et al., 2006) as well as contributing to tumor cellular
heterogeneity (Geyer et al., 2010). EMT in epithelial tumors is
associated with increased invasiveness, therapeutic resistance,
and potentially, the generation of cells with cancer stem cell-like
properties (Polyak and Weinberg, 2009). The Blg-Cre tumors
expressed EMT-associated genes such as Vim and Twist1
(Table S4); however, expression of these genes is a feature of
normal myoepithelial cells (Kendrick et al., 2008). Furthermore,
many (but not all) spindle cells observed in these tumors express
keratins (Table S1). It is therefore unclear to what extent expres-
sion of EMT markers in these tumors was related to a basal
differentiation program rather than to a full EMT.
Paradoxically, given the ER phenotype of most BRCA1
tumors, prophylactic oophorectomy provides protection against
breast cancer inBRCA1mutation carriers (Rebbeck et al., 2002).
Because estrogen stimulates proliferation of mammary epithelial
cell growth in a paracrine manner (Mallepell et al., 2006),
oophorectomy may block paracrine stimulation of a preneoplas-
tic clone originating in an ER stem or progenitor cell. Indeed,
ovariectomy in mice resulted in a decrease in cyclin D1 gene
expression in basal, luminal progenitor, and mature luminal cells
(Asselin-Labat et al., 2010). Alternatively, if there is a role for ER+
progenitors in the origin of at least a subset of BRCA1 breast
cancers, as noted above, then oophorectomy might also act
directly to block the early neoplastic progression ER+ BRCA1
tumors. Finally, it is formally possible that all BRCA1 tumors,
no matter their ER status, originate in ER+ progenitors and that
oophorectomy therefore directly blocks their early growth.
Although we cannot definitively exclude a luminal ER+ progenitor
origin for some Blg-Cre Brca1f/f p53+/ tumors, both our data
and recent work from Lim and colleagues (Lim et al., 2009)
strongly favor an origin of the majority of BRCA1 tumors in
luminal ER progenitors and thus support a model of oophorec-
tomy interfering with paracrine signals in the majority of cases.
Our findings support a model in which BRCA1mutation-asso-
ciated basal-like tumors develop in luminal progenitors.Stem Cell 7, 403–417, September 3, 2010 ª2010 Elsevier Inc. 413
Table 1. Mouse Luminal ER– Genes Are Expressed in Sporadic Human Basal-like Breast Cancers in a Panel of 53 Grade-Matched
Tumors and in the NKI295 Tumor Set
53 Grade-Matched Tumor Set NKI295 Tumor Set
Symbol Unigene ID Subtype Association FDR Corrected p Value Subtype Association FDR Corrected p Value
ELF5 Hs.11713 basal-like 0 basal-like 0.00791176
FOXC1 Hs.348883 basal-like 0 basal-like 9.74E-16
RERG Hs.199487 luminal 0 luminal 6.92E-13
GABRP Hs.26225 basal-like 0.00138 basal-like 1.51E-14
SLC6A14 Hs.522109 basal-like 0.00345 basal-like 5.06E-07
KCNN4 Hs.10082 basal-like 0.003942857 basal-like 1.82E-15
CDK6 Hs.119882 basal-like 0.005366667 basal-like 3.85E-11
LYN Hs.699154 basal-like 0.005366667 basal-like 5.25E-15
CMAS Hs.311346 basal-like 0.019638462 basal-like 0.000281051
ZBED4 Hs.475208 basal-like 0.019638462 basal-like 1.88E-06
CA9 Hs.63287 basal-like 0.025875 basal-like 4.46E-10
NCALD Hs.492427 basal-like 0.033282353 basal-like 0.000825839
PIK3AP1 Hs.310456 basal-like 0.03335 basal-like 1.73E-09
DCLK1 Hs.507755 luminal 0.037785714 luminal 2.03E-06
SMOX Hs.433337 basal-like 0 NS NS
TSPAN33 Hs.27267 basal-like 0.00759 NS NS
NPAS2 Hs.156832 basal-like 0.019638462 NS NS
ITGB8 Hs.592171 basal-like 0.019714286 NS NS
SHROOM2 Hs.567236 luminal 0.02484 NS NS
ATP10B Hs.109358 basal-like 0.037785714 NS NS
TRIB2 Hs.467751 basal-like 0.037785714 NS NS
SLC1A1 Hs.444915 NS NS luminal 5.25E-15
SH3KBP1 Hs.719268 NS NS basal-like 1.28E-09
EPSTI1 Hs.546467 NS NS basal-like 1.52E-08
NAV3 Hs.655301 NS NS luminal 5.50E-08
CCL5 Hs.514821 NS NS basal-like 5.95E-08
MUC1 Hs.89603 NS NS luminal 1.48E-07
SOX6 Hs.368226 NS NS basal-like 1.48E-07
ALDOC Hs.155247 NS NS basal-like 3.18E-07
TNFAIP2 Hs.525607 NS NS basal-like 8.38E-07
FUT9 Hs.49117 NS NS basal-like 2.03E-06
IKZF1 Hs.435949 NS NS basal-like 5.56E-06
ATP6V1B1 Hs.64173 NS NS luminal 9.87E-06
BEX4 Hs.184736 NS NS luminal 4.72E-05
BDH1 Hs.274539 NS NS luminal 8.43E-05
CLMN Hs.301478 NS NS luminal 0.000276215
PIK3CB Hs.239818 NS NS basal-like 0.000281051
CHMP1B Hs.656244 NS NS basal-like 0.000326272
CGNL1 Hs.148989 NS NS luminal 0.000542776
RPS6KA5 Hs.510225 NS NS luminal 0.000738469
CSTF2T Hs.591358 NS NS luminal 0.000825839
RAB32 Hs.287714 NS NS basal-like 0.000883334
ADCY5 Hs.593293 NS NS luminal 0.009537701
KIT Hs.479754 NS NS basal-like 0.014232944
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Table 1. Continued
53 Grade-Matched Tumor Set NKI295 Tumor Set
Symbol Unigene ID Subtype Association FDR Corrected p Value Subtype Association FDR Corrected p Value
ING3 Hs.489811 NS NS basal-like 0.020900677
DOCK8 Hs.132599 NS NS basal-like 0.027787215
Results of analysis on human breast cancers of expression of human orthologs of genes overexpressed inmouseBlg-Cre Brca1f/f p53+/ tumors that in
the normal mouse mammary tissue are associated with luminal ER cells (Kendrick et al., 2008). The distribution of the gene expression patterns was
compared in both luminal versus basal tumors (designated according to theNielsen criteria) (Nielsen et al., 2004) and in all ER-positive versus ER-nega-
tive tumors in a panel of 53 grade-matched human breast tumors. The gene expression distribution was also analyzed in the NKI295 data set
(van de Vijver et al., 2002). Only genes significantly associated with a basal-like versus luminal distribution in either of the two tumor sets are shown
above. NS, no significant association in that tumor set. See also Tables S4, S5, and S6.
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histopathological features consistent with a luminal progenitor
origin. In contrast, true breast stem cells probably are the cell
of origin of rare malignant adenomyoepithelioma. These results
demonstrate that the inherent plasticity of some types of stem
and progenitor cell, and the potential that this can be activated
in the context of tumorigenesis, means that tumor phenotype
may not simply reflect cell of origin (Gusterson, 2009). Accurate
identification of the stem or progenitor cell of origin of a particular
tumor type, however, offers the prospect of novel prophylactic
and therapeutic approaches.
EXPERIMENTAL PROCEDURES
Harvest and Processing of Tumors
Tumors of 1–1.2 cm in diameter were excised from humanely killed mice. Part
of the tumor was fixed in 4% phosphate-buffered formalin (BIOS Europe Ltd,
Skelmersdale, UK) overnight for routine histological analysis and immunohis-
tochemistry and part was snap frozen on dry ice for isolation of nucleic acids.
Where tumors were of sufficient size, a portion was also kept for flow cytomet-
ric analysis.
Flow Cytometry and Clonal Analysis
Tumor and normal mammary cell suspensions were prepared by mechanical
digestion followed by a short (30–60 min) enzymatic treatment. In the case
of normal cells, this was followed by a second round of trypsinization to liberate
single cells (Sleeman et al., 2007). Normal and tumor cell suspensions were
stained with anti-CD45-PE-Cy7, anti-CD24-FITC, and anti-Sca-1-PE. Cells
were then resuspended in medium containing 0.01% 40,6-diamidino-2-phe-
nylindole (DAPI) for analysis and cell sorting.
For clonal analysis, CD45 CD24+/low Sca-1 (basal), CD45 CD24+/high
Sca-1 (luminal ER), and CD45 CD24+/high Sca-1+ (luminal ER+) cells were
sorted into collection tubes and then resorted for extra purity. On the second
round of sorting, the cells were single cell sorted into individual wells of 96-well
plates (Nunc, Fisher Scientific UK Ltd., Leicestershire, UK) and cultured for
10 days (Sleeman et al., 2007). The plates were then fixed in 4% paraformal-
dehyde in PBS for 5 min, and stained with X-gal solution overnight at 37C.
b-galactosidase-positive colonies were scored and plates were then stained
with crystal violet overnight to assess the total number of colonies. The propor-
tion of recombined progenitors in each cell population at each developmental
stage (Figure 1E) was calculated by multiplying the colony-forming efficiency
of each population (the number of colonies formed as a proportion of the
number of single wells seeded) by the percentage of colonies that formed
which were b-galactosidase positive. Thus, for the virgin 12-week CD24+/high
Sca-1 population, the proportion of recombined progenitors in this popula-
tion was (709/(96 3 11))% 3 76.8% = 51.6%.
Histology and Immunohistochemistry
Immunohistochemistry was carried out via standard techniqueswith ERa, p63,
keratin 18, and keratin 14 antibodies. Sections were analyzed by three of the
authors on a multiheaded microscope blinded to the genotype of the tumorsCelland a consensus score was rendered for each marker in each case. All
markers were semiquantitatively assessed by estimating the percentage of
morphologically unequivocal neoplastic cells displaying either nuclear
(ER and p63) or cytoplasmic (K14 and K18) staining.
Cleared Fat Pad Transplantation
Sorted mammary tumor subpopulations were transplanted at varying dilutions
into cleared fat pads of 8–10 g Rag/ immune-deficient mice. Once tumors
appeared, they were processed as above. If tumors had not appeared after
6 months, mice were humanely killed and fat pads examined by wholemount-
ing for any evidence of outgrowths.
Microarray Analysis of Tumor Gene Expression Patterns
Transcriptome analysis on tumor RNA isolated via the RNeasy Mini Kit
(QIAGEN,West Sussex, UK) was carried out by Almac Diagnostics (Craigavon,
UK) with Affymetrix 430_0.2 mouse gene expression chips. The raw data from
normal cell populations was reanalyzed together with the raw data from the
tumors to ensure that the analyses were comparable. Raw Affymetrix .CEL
files were normalized via robust multiarray analysis (Irizarry et al., 2003) in
the Affymetrix package from BioConductor (http://bioconductor.org/). With
the previously established 2184 probe sets shown to robustly distinguish
between normal mouse mammary basal, luminal ER, and luminal ER+
mammary cells (Kendrick et al., 2008), all normal and tumor samples were
clustered based on Ward clustering via an uncentered Pearson’s correlation.
The relationship of each individual tumor to the normal cell populations was
determined by PAM (prediction analysis of microarrays) (Tibshirani et al.,
2002) with either all probes or the 2184 cell-type-specific probe subset.
SOM (self-organizing map) analysis was carried out on the ROCK platform
(http://rock.icr.ac.uk), also using the 2184 probe subset, on a 33 3 grid using
a Pearson’s Correlation similarity metric.
Quantitative Real-Time rtPCR
qPCR was carried out with TAQMAN (Applied Biosystems, Warrington, UK)
Assays-on-Demand probes on freshly isolated RNA (Kendrick et al., 2008).
Results were analyzed with the D-DCt method normalized to b-actin and
compared to a comparator sample (normal luminal ER cells).
Correlation of Blg-Cre Brca1f/f p53+/– Tumors with Human Gene
Expression Data Sets
Spearman’s rank correlations were performed for each mouse tumor sample
between the published human centroids for luminal A, luminal B, HER2, normal
breast-like, and basal-like breast cancers as described by Hu and colleagues
and Parker and colleagues (Hu et al., 2006; Parker et al., 2009). Tumors were
assigned to one of the molecular subtypes based on the highest correlation
coefficient between their expression profile and the five individual centroids
of the molecular subtypes (i.e., basal-like, HER2, normal breast-like, luminal A,
and luminal B).
Analysis of Gene Expression Data in Human Breast Cancers
A two-tailed t test was carried out on the expression levels within breast cancer
subtypes of the human orthologs of genes expressed at high levels in both
normal mouse luminal ER cells and the Blg-Cre Brca1f/f p53+/ tumors. Two
tumor data sets were used: a cohort of 53 consecutive grade 3 IDC-NSTsStem Cell 7, 403–417, September 3, 2010 ª2010 Elsevier Inc. 415
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Luminal Origin of Basal-like Breast Cancers(Natrajan et al., 2010) and the NKI295 data set (van de Vijver et al., 2002).
Results were corrected with false discovery rate (FDR) correction. Genes
were considered to be significantly associated with a breast cancer subtype
if the FDR-corrected p value was <0.05.
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